Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

A clinical review of inhalation anesthesia with sevoflurane: from early research to emerging topics.

Brioni JD, Varughese S, Ahmed R, Bein B.

J Anesth. 2017 Oct;31(5):764-778. doi: 10.1007/s00540-017-2375-6. Epub 2017 Jun 5. Review.

2.

Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.

Hudzik TJ, Basso A, Boyce-Rustay JM, Bracken W, Browman KE, Drescher K, Esbenshade TA, Loberg LI, Lynch JJ 3rd, Brioni JD.

Psychopharmacology (Berl). 2013 Jul;228(2):187-97. doi: 10.1007/s00213-013-3027-7. Epub 2013 Feb 28.

PMID:
23455597
3.

Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.

Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD.

J Pharmacol Exp Ther. 2012 Oct;343(1):233-45. doi: 10.1124/jpet.112.194126. Epub 2012 Jul 19.

PMID:
22815533
4.

Antagonism of supraspinal histamine H3 receptors modulates spinal neuronal activity in neuropathic rats.

McGaraughty S, Chu KL, Cowart MD, Brioni JD.

J Pharmacol Exp Ther. 2012 Oct;343(1):13-20. doi: 10.1124/jpet.112.194761. Epub 2012 Jun 22.

PMID:
22729221
5.

Pharmacological characterization of A-960656, a histamine H₃ receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain.

Cowart M, Hsieh G, Black LA, Zhan C, Gomez EJ, Pai M, Strakhova M, Manelli A, Carr T, Wetter J, Lee A, Diaz G, Garrison T, Brioni JD.

Eur J Pharmacol. 2012 Jun 5;684(1-3):87-94. doi: 10.1016/j.ejphar.2012.03.048. Epub 2012 Apr 5.

PMID:
22504024
6.

In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.

Bitner RS, Markosyan S, Nikkel AL, Brioni JD.

Neuropharmacology. 2011 Feb-Mar;60(2-3):460-6. doi: 10.1016/j.neuropharm.2010.10.026. Epub 2010 Oct 31.

PMID:
21044639
7.

Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.

Altenbach RJ, Black LA, Strakhova MI, Manelli AM, Carr TL, Marsh KC, Wetter JM, Wensink EJ, Hsieh GC, Honore P, Garrison TR, Brioni JD, Cowart MD.

J Med Chem. 2010 Nov 11;53(21):7869-73. doi: 10.1021/jm100666w.

PMID:
20945906
8.

Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.

Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD.

J Pharmacol Exp Ther. 2011 Jan;336(1):38-46. doi: 10.1124/jpet.110.166876. Epub 2010 Sep 23. Review.

PMID:
20864505
9.

Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems.

Hsieh GC, Honore P, Pai M, Wensink EJ, Chandran P, Salyers AK, Wetter JM, Zhao C, Liu H, Decker MW, Esbenshade TA, Cowart MD, Brioni JD.

Brain Res. 2010 Oct 1;1354:74-84. doi: 10.1016/j.brainres.2010.07.083. Epub 2010 Aug 1.

PMID:
20682302
10.

In vitro studies on a class of quinoline containing histamine H3 antagonists.

Liu H, Altenbach RJ, Diaz GJ, Manelli AM, Martin RL, Miller TR, Esbenshade TA, Brioni JD, Cowart MD.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300. doi: 10.1016/j.bmcl.2010.04.045. Epub 2010 Apr 18.

PMID:
20457525
11.

Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring.

Koenig JR, Liu H, Drizin I, Witte DG, Carr TL, Manelli AM, Milicic I, Strakhova MI, Miller TR, Esbenshade TA, Brioni JD, Cowart M.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1900-4. doi: 10.1016/j.bmcl.2010.01.131. Epub 2010 Feb 1.

PMID:
20171098
12.

H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats.

Hsieh GC, Chandran P, Salyers AK, Pai M, Zhu CZ, Wensink EJ, Witte DG, Miller TR, Mikusa JP, Baker SJ, Wetter JM, Marsh KC, Hancock AA, Cowart MD, Esbenshade TA, Brioni JD, Honore P.

Pharmacol Biochem Behav. 2010 Mar;95(1):41-50. doi: 10.1016/j.pbb.2009.12.004. Epub 2009 Dec 11.

PMID:
20004681
13.

Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.

Zhao C, Sun M, Bennani YL, Miller TR, Witte DG, Esbenshade TA, Wetter J, Marsh KC, Hancock AA, Brioni JD, Cowart MD.

J Med Chem. 2009 Aug 13;52(15):4640-9. doi: 10.1021/jm900480x.

PMID:
19588934
14.

Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.

Miller TR, Milicic I, Bauch J, Du J, Surber B, Browman KE, Marsh K, Cowart M, Brioni JD, Esbenshade TA.

Br J Pharmacol. 2009 May;157(1):139-49. doi: 10.1111/j.1476-5381.2009.00239.x.

15.

In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.

Strakhova MI, Cuff CA, Manelli AM, Carr TL, Witte DG, Baranowski JL, Vortherms TA, Miller TR, Rundell L, McPherson MJ, Adair RM, Brito AA, Bettencourt BM, Yao BB, Wetter JM, Marsh KC, Liu H, Cowart MD, Brioni JD, Esbenshade TA.

Br J Pharmacol. 2009 May;157(1):44-54. doi: 10.1111/j.1476-5381.2009.00236.x.

16.

Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.

Wang X, Sarris K, Kage K, Zhang D, Brown SP, Kolasa T, Surowy C, El Kouhen OF, Muchmore SW, Brioni JD, Stewart AO.

J Med Chem. 2009 Jan 8;52(1):170-80. doi: 10.1021/jm801042a.

PMID:
19072118
17.

Localization of histamine H4 receptors in the central nervous system of human and rat.

Strakhova MI, Nikkel AL, Manelli AM, Hsieh GC, Esbenshade TA, Brioni JD, Bitner RS.

Brain Res. 2009 Jan 23;1250:41-8. doi: 10.1016/j.brainres.2008.11.018. Epub 2008 Nov 19.

PMID:
19046950
18.

cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.

Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD.

J Med Chem. 2008 Nov 27;51(22):7094-8. doi: 10.1021/jm8007618.

PMID:
18983139
19.

Cloning and characterization of the monkey histamine H3 receptor isoforms.

Strakhova MI, Fox GB, Carr TL, Witte DG, Vortherms TA, Manelli AM, Miller TR, Yao BB, Brioni JD, Esbenshade TA.

Eur J Pharmacol. 2008 Dec 28;601(1-3):8-15. doi: 10.1016/j.ejphar.2008.10.026. Epub 2008 Oct 21.

PMID:
18977214
20.

Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.

Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I, Miller TR, Witte DG, Wishart N, Fix-Stenzel SR, McPherson MJ, Adair RM, Wetter JM, Bettencourt BM, Marsh KC, Sullivan JP, Honore P, Esbenshade TA, Brioni JD.

J Med Chem. 2008 Oct 23;51(20):6547-57. doi: 10.1021/jm800670r. Epub 2008 Sep 26.

PMID:
18817367
21.

Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.

Altenbach RJ, Adair RM, Bettencourt BM, Black LA, Fix-Stenzel SR, Gopalakrishnan SM, Hsieh GC, Liu H, Marsh KC, McPherson MJ, Milicic I, Miller TR, Vortherms TA, Warrior U, Wetter JM, Wishart N, Witte DG, Honore P, Esbenshade TA, Hancock AA, Brioni JD, Cowart MD.

J Med Chem. 2008 Oct 23;51(20):6571-80. doi: 10.1021/jm8005959. Epub 2008 Sep 24.

PMID:
18811133
22.

A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.

Miller TR, Baranowski JL, Estvander BR, Witte DG, Carr TL, Manelli AM, Krueger KM, Cowart MD, Brioni JD, Esbenshade TA.

Assay Drug Dev Technol. 2008 Jun;6(3):339-49. doi: 10.1089/adt.2007.118.

PMID:
18593375
23.

The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons.

Sinjoanu RC, Kleinschmidt S, Bitner RS, Brioni JD, Moeller A, Ferreira A.

Neurochem Int. 2008 Sep;53(3-4):79-88. doi: 10.1016/j.neuint.2008.06.003. Epub 2008 Jun 12.

24.

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD.

Br J Pharmacol. 2008 Jul;154(6):1166-81. doi: 10.1038/bjp.2008.147. Epub 2008 May 12. Review.

25.

Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats.

Zhu CZ, Baker S, EI-Kouhen O, Lehto SG, Hollingsworth PR, Gauvin DM, Hernandez G, Zheng G, Chang R, Moreland RB, Stewart AO, Brioni JD, Honore P.

Eur J Pharmacol. 2008 Feb 12;580(3):314-21. Epub 2007 Nov 13.

PMID:
18054908
26.

Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists.

Wang X, Kolasa T, El Kouhen OF, Chovan LE, Black-Shaefer CL, Wagenaar FL, Garton JA, Moreland RB, Honore P, Lau YY, Dandliker PJ, Brioni JD, Stewart AO.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4303-7. Epub 2007 May 16.

PMID:
17532216
27.

Characterization of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters.

Shieh CC, Brune ME, Buckner SA, Whiteaker KL, Molinari EJ, Milicic IA, Fabiyi AC, Daza A, Brioni JD, Carroll WA, Matsushita K, Yamada M, Kurachi Y, Gopalakrishnan M.

Br J Pharmacol. 2007 Jun;151(4):467-75. Epub 2007 Apr 16.

28.

Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.

Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA.

Biochem Pharmacol. 2007 Apr 15;73(8):1243-55. Epub 2007 Feb 23.

PMID:
17371699
29.

Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.

Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, Lannoye GS, Richardson P, Stewart A, Rogers JC, Brioni JD, Surowy CS.

Neuropharmacology. 2007 Mar;52(4):1095-105. Epub 2007 Jan 9.

PMID:
17217969
30.

Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.

Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC, Moreland RB, Sullivan JP, Brioni JD, Stewart AO.

J Med Chem. 2006 Dec 14;49(25):7450-65.

PMID:
17149874
31.

Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.

Nakane M, Kolasa T, Chang R, Miller LN, Moreland RB, Brioni JD.

J Pharmacol Sci. 2006 Oct;102(2):231-8.

32.

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.

El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, Hollingsworth PR, Mikusa JP, Cronin EA, Chu KL, McGaraughty SP, Uchic ME, Miller LN, Rodell NM, Patel M, Bhatia P, Mezler M, Kolasa T, Zheng GZ, Fox GB, Stewart AO, Decker MW, Moreland RB, Brioni JD, Honore P.

Br J Pharmacol. 2006 Nov;149(6):761-74. Epub 2006 Oct 3.

33.

1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.

Kolasa T, Matulenko MA, Hakeem AA, Patel MV, Mortell K, Bhatia P, Henry R, Nakane M, Hsieh GC, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino B, El Kouhen O, Marsh KC, Wetter JM, Moreland RB, Brioni JD, Stewart AO.

J Med Chem. 2006 Aug 24;49(17):5093-109.

PMID:
16913699
34.

Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.

Zheng GZ, Bhatia P, Kolasa T, Patel M, El Kouhen OF, Chang R, Uchic ME, Miller L, Baker S, Lehto SG, Honore P, Wetter JM, Marsh KC, Moreland RB, Brioni JD, Stewart AO.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4936-40. Epub 2006 Jun 30.

PMID:
16809035
35.

Association of Catsper1 or -2 with Ca(v)3.3 leads to suppression of T-type calcium channel activity.

Zhang D, Chen J, Saraf A, Cassar S, Han P, Rogers JC, Brioni JD, Sullivan JP, Gopalakrishnan M.

J Biol Chem. 2006 Aug 4;281(31):22332-41. Epub 2006 Jun 1.

36.

Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation.

Bitner RS, Nikkel AL, Otte S, Martino B, Barlow EH, Bhatia P, Stewart AO, Brioni JD, Decker MW, Moreland RB.

Neuropharmacology. 2006 Apr;50(5):521-31. Epub 2005 Dec 1.

PMID:
16324724
37.

Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.

Zheng GZ, Bhatia P, Daanen J, Kolasa T, Patel M, Latshaw S, El Kouhen OF, Chang R, Uchic ME, Miller L, Nakane M, Lehto SG, Honore MP, Moreland RB, Brioni JD, Stewart AO.

J Med Chem. 2005 Nov 17;48(23):7374-88.

PMID:
16279797
38.

A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats.

Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, Brioni JD, Moreland RB, Fox GB.

Pharmacol Biochem Behav. 2005 Sep;82(1):148-55. Epub 2005 Sep 8.

PMID:
16154186
39.

A-412997 is a selective dopamine D4 receptor agonist in rats.

Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD.

Pharmacol Biochem Behav. 2005 Sep;82(1):140-7. Epub 2005 Sep 8.

PMID:
16153699
40.

American Urological Association - 95th annual meeting.

Brioni JD, Moreland RB.

IDrugs. 2000 Jul;3(7):762-5. No abstract available.

PMID:
16080048
41.

Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels.

Dubé GR, Lehto SG, Breese NM, Baker SJ, Wang X, Matulenko MA, Honoré P, Stewart AO, Moreland RB, Brioni JD.

Pain. 2005 Sep;117(1-2):88-96. Erratum in: Pain. 2005 Nov;118(1-2):281.

PMID:
16061325
42.

2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.

Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB.

Neuropharmacology. 2005 Jul;49(1):112-21. Epub 2005 Apr 1.

PMID:
15992586
43.

Synthesis and evaluation of 3-aryl piperidine analogs as potent and efficacious dopamine D4 receptor agonists.

Wang X, Bhatia PA, Daanen JF, Latsaw SP, Rohde J, Kolasa T, Hakeem AA, Matulenko MA, Nakane M, Uchic ME, Miller LN, Chang R, Moreland RB, Brioni JD, Stewart AO.

Bioorg Med Chem. 2005 Aug 1;13(15):4667-78.

PMID:
15896964
44.

Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets.

Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB.

Pharmacol Biochem Behav. 2005 May;81(1):211-9.

PMID:
15894081
45.

Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test.

Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, Drescher K, Fox GB, Decker MW, Rueter LE.

Neuropsychopharmacology. 2005 Jul;30(7):1257-68.

46.

Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats.

Polakowski JS, Segreti JA, Cox BF, Hsieh GC, Kolasa T, Moreland RB, Brioni JD.

Clin Exp Pharmacol Physiol. 2004 Dec;31(12):837-41.

PMID:
15659045
47.

Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand.

Matulenko MA, Surber B, Fan L, Kolasa T, Nakane M, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL, Namovic MT, Moreland RB, Brioni JD, Stewart AO.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5095-8.

PMID:
15380206
48.

[3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.

Moreland RB, Terranova MA, Chang R, Uchic ME, Matulenko MA, Surber BW, Stewart AO, Brioni JD.

Eur J Pharmacol. 2004 Aug 23;497(2):147-54.

PMID:
15306199
49.

Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).

Moreland RB, Nakane M, Donnelly-Roberts DL, Miller LN, Chang R, Uchic ME, Terranova MA, Gubbins EJ, Helfrich RJ, Namovic MT, El-Kouhen OF, Masters JN, Brioni JD.

Biochem Pharmacol. 2004 Aug 15;68(4):761-72.

PMID:
15276084
50.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.

Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ 3rd, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO.

J Med Chem. 2004 Jul 15;47(15):3853-64.

PMID:
15239663

Supplemental Content

Loading ...
Support Center